Kubota K, Mizoguchi H, Miura Y, Muto Y, Chiyoda S, Takaku F
Am J Hematol. 1978;5(4):285-90. doi: 10.1002/ajh.2830050402.
For the purpose of preventing a relapse of acute leukemia which is currently the major problem in the successful treatment of the disease, repeated consolidation or intensification therapy during the first year following remission is important. To evaluate these therapies, we investigated the serial changes in CFU-C's of the marrow cells from 12 patients with acute nonlymphocytic leukemia in remission and tried to estimate the relationship between the intensity of consolidation or intensification therapy and the duration of remission, utilizing the degree of reduction in CFU-C's seven days after these treatments as an indicator. As a result, after 21 out of 22 courses of therapy where CFU-C's were reduced significantly after the therapy, the patients were still in remission at the time of the next intensificiation therapy (at most for about 100 days). On the other hand, after five out of ten courses where CFU-C's were not reduced significantly, the patients were in relapse at the time of the next intensification therapy. From these results, it may be inferred that cases whose CFU-C's are not reduced significantly should be treated intensively again within a short period.
为预防急性白血病复发（这是目前该疾病成功治疗中的主要问题），在缓解后的第一年进行反复的巩固或强化治疗很重要。为评估这些治疗方法，我们调查了12例急性非淋巴细胞白血病缓解期患者骨髓细胞集落形成单位 - 细胞（CFU - C）的系列变化，并试图以这些治疗后七天CFU - C的降低程度为指标，估算巩固或强化治疗强度与缓解期持续时间之间的关系。结果，在22个疗程中有21个疗程治疗后CFU - C显著降低，在下一次强化治疗时（最长约100天）患者仍处于缓解期。另一方面，在10个疗程中有5个疗程CFU - C未显著降低，在下一次强化治疗时患者出现复发。从这些结果可以推断，CFU - C未显著降低的病例应在短时间内再次进行强化治疗。
